Editas Medicine Inc. (0IFK)
LSE 
Summary
0IFK Chart
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.
Editas Medicine Inc. (0IFK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Editas Medicine Inc. ever had a stock split?
Editas Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gilmore O'Neill CEO | LSE Exchange | 28106W103 CUSIP |
| US Country | 87 Employees | - Last Dividend | - Last Split | 3 Feb 2016 IPO Date |
Overview
Editas Medicine, Inc. is a trailblazer in the emerging field of genome editing, signifying its pivotal role in ushering in a new era of genomic medicine aimed at confronting severe diseases head-on. Established on the cutting-edge CRISPR technology, this company stands out in its commitment to leverage gene editing for the creation of groundbreaking medical treatments. It embarked on its mission under the name Gengine, Inc. before transitioning to Editas Medicine, Inc. in November 2013, marking a new chapter in its quest to redefine medical treatment through genetic innovation. Based in the innovation hub of Cambridge, Massachusetts, Editas Medicine, Inc. is intensely involved in clinical-stage research and development, striving to transform the landscape of medical therapeutics through its dedication to scientific excellence and patient-centered care.
Products and Services
- EDIT-101
A pioneering product in Phase 1/2 BRILLIANCE trial, EDIT-101 targets Leber Congenital Amaurosis, aiming to offer a significant leap forward in treating this genetic disorder. This product exemplifies Editas Medicine's innovative use of CRISPR technology for direct, transformative medical interventions.
- Reni-cel
Also known as a gene-edited medicine in clinical development, reni-cel holds the promise for treating sickle cell disease and transfusion-dependent beta-thalassemia. By addressing the genetic roots of these conditions, reni-cel represents a new horizon in therapeutic strategies for blood disorders.
- Alpha-beta T Cells
These are being developed for the treatment of solid and liquid tumors, representing a novel approach in the fight against cancer. Through the engineering of T cells, Editas aims to harness the body's immune system to target and eliminate cancerous cells, highlighting the therapeutic potential of gene editing in oncology.
- Gamma Delta T Cell Therapies
Focused on cancer treatment, these therapies are part of Editas Medicine’s broader strategy to develop innovative cancer treatments through the manipulation of the immune system. Gamma delta T cell therapies represent a cutting-edge direction in immunotherapy, aimed at overcoming some of the toughest challenges in cancer care.
